Comparability to Remicade as measured by ACR20 response in severe rheumatoid arthritis (RA) patients No meaningful differences observed in safety or immunogenicity First market authorization filing in ...
A low-profile startup in Boston backed by some marquee venture groups has posted positive data from a Phase III study of its biosimilar of Remicade, a blockbuster rheumatoid arthritis drug. Epirus ...
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today ...
Orygen Biotecnologia will develop, manufacture, and commercialize several products of Epirus Biopharmaceuticals in Brazil, starting with a biosimilar version of the arthritis drug Remicade (infliximab ...
EPIRUS Biopharmaceuticals, Inc. (EPIRUS), a privately held biotechnology company focused on the development and production of biosimilar products for major emerging markets, today announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results